Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Medical University of South Carolina
Sponsor:
Collaborator:
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Luciano J. Costa, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01690143
First received: July 17, 2012
Last updated: October 30, 2012
Last verified: October 2012
  Purpose

This study is for patients that have multiple myeloma that has come back or relapsed and their condition indicates a procedure called an Autologous Hematopoietic Stem Cell Transplantation (AHSCT). AHSCT is a procedure when stem cells from bone marrow or blood are removed before high-dose chemotherapy. Afterwards, the removed stem cells are put back into the patient's body to form a new population of blood cells.

The high-dose chemotherapy administered before the AHSCT is called "Conditioning Therapy." The FDA has approved the use of the drug melphalan as a conditioning therapy. This research study will look at whether adding the study drug called carfilzomib will improve participant outcomes. Carfilzomib is considered investigational and is not approved by the FDA for the treatment of relapsed multiple myeloma.

This study is divided into two phases.

Phase I: Dose Escalation Phase:

The main purpose of Part I of this study is to examine the safety of the study drug, carfilzomib, and determine the safest amount of the study drug that can be given to subjects who have multiple myeloma. Subjects on this study will receive different dose levels of the study drug. If you are one of the first three subjects to receive the study drug, it will be at what is called the 'starting dose' for the study which is the lowest dose that is expected to be tolerated based on prior research. After the first set of participants receive the study drug, the study doctor will review their health to see how they are tolerating the treatment. This will decide if the study drug dosage will be increased or decreased for the next set of subjects who join the study. It is anticipated that 12- 18 participants will enroll in the Phase I portion of this study.

Phase II: Safety Confirmation Phase:

Once the study doctor has discovered the highest possible dose of study drug that subjects can tolerate, up to 28 more subjects may be enrolled at that dose level. The main purpose of the Phase II portion of the study is look at how effective the combination of carfilzomib and melphalan when given before your stem cell transplantation is in treating multiple myeloma.


Condition Intervention Phase
Multiple Myeloma
Drug: Carfilzomib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • To determine the Maximum Tolerated Dose (MTD) of carfilzomib plus melphalans conditioning for AHSCT in patients with relapsed Multiple Myeloma(MM) [Phase I portion of study] [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]
  • To evaluate efficacy of carfilzomib plus melphalan conditioning in patients with relapsed MM [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]
  • To evaluate toxicity and tolerability of carfilzomib plus melphalan conditioning in patients with relapsed MM. [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To investigate the pharmacodynamic effects of carfilzomib + high dose melphalan in terms of changes in expression of fanconi anemia/BRCA DNA repair genes and DNA fragmentation [ Time Frame: 4 1/2 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 58
Study Start Date: May 2012
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Carfilzomib + high dose melphalan
Single arm.
Drug: Carfilzomib
Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. On day -2, with 60 to 120 minutes of the end of infusion of carfilzomib, subjects will receive 200 mg/m2 of intravenous melphalan as an intravenous push or a fast infusion, according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.

  Hide Detailed Description

Detailed Description:

This is a phase 1/2a trial. Since this is an AHSCT conditioning regimen trial, only one cycle of therapy will be administered for each subject.

PHASE 1 The phase 1 component has a typical 3+3 design.

  • Initially up to three subjects will be enrolled in each cohort starting at cohort 0 in the table below.
  • If no dose limiting toxicity (DLT) is noted among the 3 initial subjects, 3 additional patients will be accrued at the subsequent cohort.
  • If 1/3 subjects experience DLT, 3 additional subjects will be accrued at the cohort. If no additional DLT occur, accrual will continue at the subsequent cohort.
  • If 2 or more subjects experience DLT in a given cohort, the dose will be considered higher than the maximum tolerated dose (MTD) and the immediately lower dose will be considered the MTD.
  • If accrual is completed in cohort 4 with 0/3 or 1/6 DLT, the MTD will be considered "not reached" and cohort 4 will be expanded in the phase 2 of the trial.
  • If 2 subjects experience DLTs in cohort 0, patients will be accrued in cohort -1, one subject at a time, with the subsequent subject only being accrued once the current subject has completed the DLT period (transplant day 30). The doses in cohort -1 will be considered the MTD if 0/3 or 1/6 subjects experience DLT.
  • If ≥ 2 subjects experience DLT in cohort -1 the study will be interrupted without proceeding to phase 2a and the combination of carfilzomib and high dose melphalan will be considered too toxic.

PHASE 2 Once the MTD for the combination of carfilzomib and high dose melphalan with AHSCT is found, there will be expansion of the MTD cohort so that 28 individuals will be treated at the MTD of carfilzomib and high dose melphalan.

Screening - Subjects likely to meet eligibility criteria will be offered participation in the study after the investigator verifies with the registration system that there is a current available slot (phase 1). Subjects will sign informed consent prior to any protocol associated procedure. Screening procedures are outlined in Table 3 and will 1) ensure that subject meets all the eligibility criteria, 2) obtain disease assessment to allow efficacy measurements, 3) assess baseline toxicity and 4) provide initial biological samples for pharmacodynamic and correlative studies.

Treatment- Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. On day -2, with 60 to 120 minutes of the end of infusion of carfilzomib, subjects will receive 200 mg/m2 of intravenous melphalan as an intravenous push or a fast infusion, according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.

Infusion of autologous cells- Infusion of autologous hematopoietic stem cells will occur on day 0 and follow institutional SOP.

Follow up phase - On day 1 following HSCT patients will receive pegfilgrastim 6 mg subcutaneously as per institutional standard of care aiming at faster engraftment. The follow up phase will last 100 days and will consist of standard post transplantation supportive care and monitoring of AEs. For the phase 1 component of the study, dose-limiting toxicities will be captured during the first 30 days after transplantation (DLT period).

Disease assessment- Disease assessment will occur at day 100 (+/- 7 days) and will consist of serum protein electrophoresis, serum and urine immunofixation, 24h urine protein electrophoresis, serum free light chains, bone marrow aspiration and biopsy, complete blood counts and metabolic panel.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 70 years
  2. Life expectancy ≥ 12 months
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  4. Diagnosis of symptomatic multiple myeloma38, relapsed after initial therapy.
  5. At least minimal response (defined as 25% decrease in the M protein in serum or urine) to the most recent treatment regimen.
  6. Evaluable disease prior to most recent treatment regimen as defined by at least one of the following:

    • Serum monoclonal (M) protein ≥0.5 g/dl by protein electrophoresis

      • 200 mg of M protein in the urine on 24 hour electrophoresis
    • Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
    • Monoclonal bone marrow plasmacytosis ≥30%
  7. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to start of therapy
  8. Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to start of therapy (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
  9. Creatinine clearance (CrCl) ≥ 40 mL/minute within 14 days prior to start of therapy, either measured or calculated using a standard formula (eg, Cockcroft and Gault).
  10. Prior storage of at least 2 x 106 CD34+ cells/kg available for autologous transplantation. During the phase 1 component of the study, at least the same amount of cells is required as "back up" in the unlikely event of non-engraftment.
  11. Subjects may have had a prior AHSCT for the treatment of MM as long as it was performed greater than 12 months from study registration.
  12. Subjects must meet institutional general eligibility criteria for autologous transplantation.
  13. Written informed consent in accordance with federal, local, and institutional guidelines.
  14. Female of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.
  15. Male subjects must agree to practice contraception.

Exclusion Criteria:

  1. Pregnant or lactating females.
  2. Major surgery within 30 days prior to start of treatment.
  3. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization.
  4. Known human immunodeficiency virus infection.
  5. Active hepatitis B or C infection.
  6. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.
  7. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization.
  8. Nonhematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.
  9. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization.
  10. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
  11. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.
  12. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01690143

Contacts
Contact: Jessica Simons 843-792-8856 simonsjl@musc.edu
Contact: Tricia Bentz, CCRP 843-792-1753 adraleta@musc.edu

Locations
United States, New York
Memorial Sloane Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Sergio Giralt, MD    212-639-6009      
United States, South Carolina
Medical University of South Carolina Hollings Cancer Center Recruiting
Charleston, South Carolina, United States, 29425
Contact: Jessica Simons    843-792-8856    simonsjl@musc.edu   
Contact: Tricia Bentz, CCRP    843-792-1753    adraleta@musc.edu   
Principal Investigator: Luciano Costa, MD         
Sub-Investigator: Robert Stuart, MD         
Sub-Investigator: Yubin Kang, MD         
Sponsors and Collaborators
Medical University of South Carolina
Onyx Pharmaceuticals
Investigators
Principal Investigator: Luciano Costa, MD Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Luciano J. Costa, Associate Professor of Medicine, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT01690143     History of Changes
Other Study ID Numbers: CTO 101669, Onyx IST-CAR-536
Study First Received: July 17, 2012
Last Updated: October 30, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Melphalan
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 22, 2014